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ABSTRACT - DIABETIC OSTEOPATHY. A STUDY IN THE RAT 
Tashfeen Ahmad, MD, Dept. of Surgical Sciences, Section of Orthopedics, Karolinska Institutet, Stockholm. 
The present study on non-obese Goto-Kakizaki (GK) rats with type-2 diabetes and neuropathy 
was an attempt to describe and define pertinent features of diabetic osteopathy. Altogether, the 
study included 33 GK rats aged 12 and 20 months, and 36 age-matched Wistar rats as controls. 
All underwent test of glucose tolerance and nerve (sciatic) conduction velocity (NCV) showing 
that the diabetic rats had significantly higher blood glucose levels and lower NCV confirming 
the presence of diabetes and neuropathy. 
Skeletal features Radiologic analysis of bone entailed X-ray, Dual Energy X-ray 
Absorptiometry (DEXA) and peripheral Quantitative Computed Tomography (pQCT). In 
diabetic rats, the length of humerus and height of vertebrae was reduced by 8%. The long bones 
exhibited endosteal erosion of the diaphyses up to 18% and periosteal expansion up to 8%. The 
vertebrae and metaphyses of long bones showed a decrease up to 24% in areal bone mineral 
density (BMD), whereas no decrease was seen in the diaphyses. Cross-sectional measurements 
by pQCT showed a decrease in volumetric BMD ranging from 33 to 62%, which exclusively 
pertained to trabecular bone (vertebrae, metaphyses), whereas volumetric BMD of the cortical 
bone of diaphyses was only marginally affected. The results indicate that juxta-articular bone in 
diabetes is substantially weaker, whereas diaphyseal cortical bone may be even stronger. Over 
all, the observations suggest that the diabetic skeleton is characterized by regional changes, 
which cannot be explained by systemic factors like calcium regulating hormones. Local bone 
turn-over is regulated by complex mechanisms involving cytokines, prostaglandins, growth 
factors and, also neuropeptides. Further analysis focused on the insulin-like growth factor (IGF) 
system and neuronal mediators in bone. 
IGF system Immunoassays of IGF-I were done on serum, ankle samples and cortical 
preparations. In addition, the inhibitory IGF-I binding proteins, IGFBP-1 and -4 were analysed 
in serum. In diabetic rats, serum IGF-I was reduced by 18%, while IGFBP-1 and IGFBP-4 were 
increased by 89 and 20 %, respectively. This complies with the lower BMD in the diabetic rats. 
In cortical bone, IGF-I was reduced by 38%, whereas no change was seen in ankles. The loss of 
IGF-I in cortical bone represents a novel finding. Given the cortical expansion observed in 
diabetic rats, the opposite was expected. Conceivably, loss of IGF-I results in endosteal erosion, 
which is compensated by periosteal expansion. 
Neuropeptides The analyses focused on two sensory mediators, i.e. substance P (SP) and 
calcitonin gene-related peptide (CGRP), and one autonomic, i.e. neuropeptide Y (NPY). 
Immunohistochemistry was applied to ankles and tibial diaphyses, whereas radioimmunoassay 
(RIA) was used for separate preparations of periosteum, cortex and bone marrow from femur 
and tibia, whole ankles, dorsal root ganglia (DRG) and lumbar spinal cord. The morphological 
analysis showed SP, CGRP and NPY positive nerve fibers in bone and joints, which mostly 
were blood vessel related, although free terminals were also seen. In addition, NPY-positive 
hematopoietic cells were observed in the bone marrow. RIA revealed a significant decrease of 
CGRP, albeit not of SP, in DRG (-26%) and spinal cord (-29%) in the diabetic rats. As for bone, 
only NPY was significantly reduced, most evidently in bone marrow (-66%), but also in cortical 
bone (-36%) and ankles (-29%). Given the bone anabolic effects of CGRP and NPY, loss of 
these neuropeptides may prove, at least partly, to underlie the trabecular osteopenia and 
endocortical erosion observed in diabetic rats.  
Conclusion The skeleton of diabetic rats with type-2 diabetes and neuropathy is characterized 
by regional changes of size, form, mineral content and density and concomitantly with regional 
abnormalities of the IGF-system and neuropeptides suggesting that also local factors beyond 
systemic play an important role in the development of diabetic osteopathy. 
Key words: Diabetes mellitus type 2, Goto-Kakizaki rat, bone mineral density, insulin-like growth 
factor-I, insulin-like growth factor binding protein 1, insulin-like growth factor binding protein 4, 
peripheral neuropathy, substance P, calcitonin gene-related peptide, neuropeptide Y 
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BACKGROUND 
The world prevalence of diabetes mellitus is estimated to be around 150 
million, out of which 85-95% are being afflicted by the type 2 variant1. The 
prevalence is projected to increase worldwide to 300 million people by 
20252,3. Given the high rate of morbidity, the disorder will place a 
tremendous burden on the health care systems4. Among diabetes patients 
10-30% have angiopathy, 35-70% retinopathy, 15-40% nephropathy and 
60-70% neuropathy5. In addition to these classical complications, 
accumulating data suggests that diabetic patients are at increased risk of 
developing osteopathic changes, although the nature and prevalence of 
this complication are still a matter of dispute. 
DIABETIC OSTEOPATHY 
Today it is widely recognized that patients with diabetes have an 
increased risk of sustaining fractures6,7. Diabetes is also associated with 
impaired fracture healing; the fracture callus in diabetes is slow to appear 
and mature, and there is a high rate of non-unions8. In diabetic animals, 
the fracture callus is weaker than normal9. The decreased mechanical 
strength has been attributed to decreased collagen synthesis9. Clinically, 
it is also well known that the complication rate of fracture treatment in 
diabetes is elevated because of increased susceptibility to infections, non-
union, implant failure and re-dislocation, sometimes even prompting 
amputation. Altogether, it now seems well established that patients with 
diabetes have a higher incidence and morbidity from fracture as compared 
to non-diabetic subjects. In addition, clinical diabetes is associated with an 
increased incidence of spontaneous collapse of subchondral bone in load-
bearing joints and development of Charcot arthropathy10 (Fig.1).  
In diabetes, abnormalities of the endocrine organs such as the 
hypothalamus, pituitary, adrenal, thyroid, parathyroid and the gonads as 
well as the endocrine function of the adipose tissue and the vitamin D 
system have been reported11. However, it is unknown to what extent each 
of these disorders affects bone turn-over in diabetes. Most studies on 
diabetic osteopathy suggest that it is a form of low turn-over osteoporosis 
without hyperparathyroidism or osteomalacia12-16, though increased bone 
resorption has also been reported17. 
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Figure 1 (A-C). Diabetic osteopathy 
Spontaneous fracture of the fibula and neuropathic osteoarthropathy of the foot in a 63-year-
old diabetic woman. Anteroposterior (A) and lateral (B) radiographs of the ankle show 
disruption of the subtalar joint (black arrow in B), talonavicular subluxation, and fracture of 
the distal fibula (white arrow in A and B). The lateral radiograph (C) depicts neuropathic 
osteoarthropathy of the ankle and hindfoot in a 42-year-old diabetic man. The distal tibia is 
resorbed and has sharp margins resembling surgical amputation. The talar dome is resorbed. 
Sclerosis is present, and subtalar joints (arrows) can no longer be identified.Pictures are 
copyright of RadioGraphics Online (http://radiographics.rsnajnls.org/) and are reproduced with 
permission from the Radiological Society of North America. 
Taken together it appears that bone in diabetes is different from normal. 
The above features are often referred to as “diabetic osteopathy”. However, 
the exact nature of this disorder has so far not been well defined, nor have 
the underlying mechanisms been clarified. This may explain why there is 
still a lack of consensus about diabetic osteopathy, despite substantial 
evidence pointing to its existence. To some extent, this can be explained by 
lack of appropriate definitions of the pertinent features of the disorder. This 
in turn can be ascribed to differences in the variables considered and 
methodologies employed.   
 
ANALYTIC APPROACH 
By far the commonest non-invasive method for assessment of bone 
structure is dual energy X-ray absorptiometry (DEXA), which is routinely 
used to evaluate osteoporosis18. In the diabetic population, bone 
densitometric studies have revealed a lower than normal bone mineral 
density. However, findings on BMD vary between type-1 and type-2 
diabetes. In type-1 diabetes, most studies show a lower bone mineral 
density (BMD), but in type-2 diabetes lower, normal and even higher BMD 
has been reported19-21. The increased BMD in type-2 diabetes primarily 
A B C 
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pertains to the lumbar vertebrae, while peripheral sites such as femoral 
neck and distal radius frequently exhibit a lower BMD. Thus, type of 
diabetes seems to be one determinant of the bone changes, but the 
difficulties in obtaining conclusive data on diabetic bone are also due to 
confounding factors such as treatment and obesity.   
Insulin therapy is likely to increase BMD because of its effect on bone22. 
Indeed, patients treated with insulin have been shown to exhibit higher 
BMD than those with oral hypoglycemic agents23. Obesity, more common in 
type-2 diabetes, is likely to protect against osteopenia since body mass 
index correlates with BMD and bone size. Thus, osteopenia due to the 
diabetes may be offset by the gain of BMD due to obesity, thereby resulting 
in a normalized BMD. 
The lack of coherent data on bone in diabetes may also be attributed to the 
shortcomings of the methodology commonly employed, i.e. DEXA. Thus, the 
method merely provides areal bone mineral density (a-BMD) from projected 
X-ray images. A large amount of age, gender and race-specific data on a-
BMD in healthy population is available, mainly for the lumbar spine, 
proximal femur and distal radius. Significant deviations from these 
findings are considered to reflect osteoporosis18. However, the 
conventionally used protocols and reference data may not be appropriate 
for osteopathic conditions other than osteoporosis. A-BMD measurements 
are highly dependent on bone size24. Thus, growing children exhibit a 
progressive increase in a-BMD just because the bones get longer and wider. 
As DEXA is based on projected radiographic images, it is not well suited for 
separate analysis of cortical and trabecular components of bone. In these 
respects, the more recently introduced quantitative computed tomography 
(QCT) technique is superior. It provides “true” volumetric BMD (v-BMD) 
independently of bone size. Notably, the v-BMD of cortical bone has been 
found to be essentially constant from childhood until middle age, but 
decreased in old age25,26. pQCT also permits separate determination of 
BMD of cortical and trabecular compartments in defined regions of a given 
bone27. Thus, for bone assessment in diseases affecting specific bone sub-
regions, pQCT is likely to be superior to DEXA, and this may be true for 
diabetic osteopathy as well. So far, however, this has not been explored. 
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MECHANISMS 
The pathomechanisms behind the skeletal changes observed in diabetes 
essentially remain unknown. It is reasonable to assume that they somehow 
are related to insulin deficiency. Insulin is a growth factor for cartilage and 
bone28,29, acting through a variety of mechanisms. In type-1 diabetes an 
absolute deficiency of insulin exists. In patients with type-2 diabetes, a 
relative deficiency exists due to peripheral insulin resistance and an 
impaired insulin release in response to glucose load, while absolute levels 
are normal or elevated. Notably, hyperglycemia has been shown to impair 
osteoblast proliferation both directly and indirectly17,30. Evidence for the 
indirect effect comes from observations of decreased sensitivity of 
osteoblasts to the effect of growth factors in the presence of 
hyperglycemia31,32. 
IGF Insulin-like growth factors (IGF) have been shown to have important 
effects on bone33-37. The first IGF to be characterized, i.e. IGF-I, is a single-
chain polypeptide of 70 amino acids produced by liver cells, but also by 
several other cell-types including osteoblasts38,39. It is called “insulin-like” 
because it bears structural homology to proinsulin, and has affinity for the 
insulin receptor. IGF-I also has a specific receptor of its own (IGF-I 
receptor). IGF-I under normal conditions is anabolic for bone33-37. IGF-I 
gene deletion leads to severe osteopenia and growth retardation40. In IGF-I 
receptor knockout mice, significant reduction in trabecular bone mass and 
deficient mineralization is seen, though growth of the bone is normal41. The 
effect of IGFs is modulated by certain proteins, known as IGF binding 
proteins (IGFBPs). To date, six different IGFBPs have been characterized. 
Apart from modulating IGF-I action42, IGFBPs also have direct effects on 
osteoblasts43,44 and osteoclasts45. In general, IGFBPs bind to IGF-I and 
reduce its bioavailability and thereby its action. In diabetes mellitus, low 
serum and tissue levels of IGF-I have been demonstrated46,47, but data on 
bone is sparse. It is quite conceivable that an abnormality of the IGF 
system underlies diabetic osteopathy. Whether the IGF-system also 
indirectly causes osteopathy through other pathways is unknown.  
Angiopathy In the feet of diabetic patients, increased blood flow 
associated with arterio-venous shunting48, and increased bone blood flow49 
have been demonstrated, most likely due to autonomic neuropathy causing 
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disturbed vasoregulation. Notably, increased bone resorption has been 
observed in the presence of increased blood flow50,51. Arterio-venous 
shunting deprives the tissues of oxygen and nutrients even though blood 
flow may appear to be increased. One of the main theories on the 
mechanism underlying Charcot joint formation, the neuro-vascular theory, 
considers osteopenia to be a result of disturbed vasoregulation caused by 
neuropathy52. 
Bone neuropathy In disorders of both the central nervous system such as 
paraplegia53 and head injury54,55 as well as those of the peripheral nervous 
system such as diabetic neuropathy56 and leprosy57 abnormal fracture 
healing and focal abnormalities of bone are observed. Peripheral 
neuropathy in diabetes is a common observation. Notably, it is a consistent 
feature of diabetic patients developing osteopathy. Neuropathy may affect 
bone through abnormal vasoregulation, but probably also has direct effects 
on bone.  
Bone innervation The first reports on bone innervation according to 
specific transmitters, i.e. neuropeptides, were published in the late 80’s by 
Bjurholm et. al58,59. Using immunohistochemistry, both sensory and 
autonomic nerve fibers in bone were identified. Most of the nerve fibers 
were found in areas of high osteogenic activity, i.e. along the osteochondral 
junction of the epiphyseal plate and the periosteum60. The nerves have been 
shown to contain a variety of neuronal mediators, including sensory, 
autonomic, opioid and immune-related peptides61. Originally, nerves in 
bone were considered mainly to have a sensory and vasoregulatory role. 
However, over the last couple of decades direct effects on bone tissue have 
been observed for several neuronal mediators, notably, so-called 
neuropeptides. Among sensory neuropeptides, substance P (SP) has a bone 
resorptive action62,63 while calcitonin gene-related peptide (CGRP) inhibits 
resorption64 and suppresses osteoclast formation and proliferation65,66. The 
SP receptor, i.e. neurokinin-1 (NK-1), has been demonstrated in 
osteoblasts, osteocytes and osteoclasts67, and evidence of their function has 
also been reported68-70. The autonomic neuropeptide vasoactive intestinal 
polypeptide (VIP) acts on both osteoclasts and osteoblasts and has a bone-
resorptive effect71. Via the central nervous system, another autonomic 
neuropeptide, i.e. neuropeptide Y (NPY), exerts an anti-osteogenic effect72. 
In the peripheral nervous system, NPY appears to have a pro-osteogenic 
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effect. It is co-released with noradrenaline from sympathetic nerves, and 
sympathectomy by surgical73 or chemical74 methods increases osteoclast 
number and surface. Moreover, NPY modulates osteoblastic response to 
noradrenaline as well as parathyroid hormone through a receptor-receptor 
interaction68,69 in vitro. Thus, it is reasonable to assume that altered 
expression of neuropeptides in disorders of the peripheral nervous system 
adversely affects bone. As for indirect effects, interactions between 
neurotransmitters on one hand and growth factors and cytokines on the 
other are well known75,76. 
Neuropathy and osteopathy Presumably, neuropathy can cause 
osteopenia through dysregulation of the direct neuropeptidergic effects on 
bone and/or disturbance of their indirect effects via growth factors and 
cytokines. Altogether, it is quite conceivable that diabetic neuropathy 
underlies diabetic osteopathy. Diabetic neuropathy is a broadly used term 
which is defined differently by people from different fields. Thus, the 
clinician defines it according to the signs and symptoms of the patient, and 
a variety of elaborate definitions and clinical tests have been advocated in 
the literature77,78. The electrophysiologist defines it e.g. by nerve conduction 
velocity, action potential amplitudes and latencies. The pathologist defines 
it according to nerve morphology. Classical findings include axonal 
degeneration (nerve cells) and demyelination (Schwann cells)79. However, 
for bone an important aspect may be the peripheral occurrence of neuronal 
mediators. Notably, in clinical and experimental studies on diabetes a 
decrease of neuropeptides has been demonstrated in tissues such as dorsal 
root ganglia80, sciatic nerve80,81, skin82 and plasma83. However, to our 
knowledge no study has been conducted to analyze the occurrence of 
neuropeptides in bone and joints in diabetes. Thus, “bone and joint 
neuropathy” from this perspective has so far not been defined. Although, 
this approach cannot provide a clinical definition, it may contribute to a 
better understanding of the pathomechanisms of neuropathy and hopefully, 
also, to the development of new therapy. 
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HYPOTHESES AND AIMS 
 
Based on the hypothesis that osteopathy in diabetes exhibits typical 
skeletal features, which may be caused by abnormalities of the IGF-system 
and the nervous system in bone and joints, the present study included the 
following aims:  
 
1. Identify the most appropriate radiological method for 
assessment of diabetic osteopathy  
2. Describe radiologically the typical skeletal features of diabetic 
osteopathy 
3. Assess the systemic as well as the local bone and joint status of 
the IGF system in diabetic osteopathy 
4. Explore and define abnormalities of the peripheral nervous 
system in diabetic osteopathy according to neuropeptide 
occurrence in bone and joints 
STUDY DESIGN   
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STUDY DESIGN 
Total number of rats = 33 diabetic Goto-Kakizaki + 36 control Wistar  
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MATERIAL 
ANIMALS 
The study included 33 Goto-Kakizaki (GK) rats84 with spontaneous type-2 
diabetes mellitus aged 12 months (Paper II-IV) and 20 months (Paper I), 
respectively. The GK rats were taken from our colony bred under 
supervision of the Department of Endocrinology and Diabetology at the 
Karolinska Hospital. The control group comprised of age-matched female 
Wistar rats (B&K Universal, Stockholm, Sweden) with normal glucose 
tolerance. The 12-month old rats were female while the 20-month old rats 
were male. The GK rat85 was originally developed from the Wistar strain by 
selective inbreeding on the basis of impaired glucose tolerance. Thus, 
Wistar rats are the only relevant controls.  
Comments An animal model was chosen because of the intention to 
analyze neuronal mediators and IGF in bone and joint tissue. A human 
study, which would entail biopsy specimens from bone and joints, was not 
considered ethically justifiable because of the inconvenience and risk of 
infection and other complications. In-vitro experiments were not an option 
since the study required an intact nervous system and a functional IGF 
axis. 
The rationale of choosing a model of type-2 diabetes instead of type-1 
pertained to insulin deficiency as a confounding factor. Most models of type-
1 diabetes as opposed to type-2 require insulin treatment for survival over a 
long period. Since insulin is a strong trophic factor for bone22, both it’s 
deficiency as well as treatment would have been a major confounding factor 
for this study in which osteopenia was an outcome parameter. Moreover, 
the prevalence of type-2 diabetes is greater than that of type-11.  
The GK rats exhibit mild to moderate hyperglycemia with onset 
early after birth86. They have normal or slightly elevated plasma insulin 
levels in the fed state, mild hypoinsulinemia in the fasting state and 
impaired insulin response to glucose. The animals develop the chronic 
complications of diabetes including angiopathy and nephropathy even 
though the metabolic abnormality is not severe. Also, the conduction 
velocity of peripheral nerves progressively declines with age, and the 
morphological changes in the nerves are very similar to those seen in 
human diabetic neuropathy87.  
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The GK-rat is not obese, unlike other rat models of type-2 diabetes. Thus, it 
may reveal effects of diabetes on bone that could be masked otherwise by 
obesity seen in other rat models e.g. Zucker diabetic fatty rat88, and in 
humans with type-2 diabetes. The appropriateness of this animal model for 
the study of osteopathy and neuropathy has been reported previously89. In 
human type-2 diabetes obesity is common. However, in the experimental 
setup it is an advantage to have a lean model, since obesity can increase 
bone mass, and thereby mask the effect of diabetes. 
Housing and care The animals were housed in cages with up to four rats 
in each cage, and cared for according to the animal department’s protocol. 
The same diet, standard rat-chow, was provided ad-lib to both diabetic and 
control rats. No treatment was given to the diabetic rats to correct the 
diabetes, since such treatment would affect bone turn-over. Notably, insulin 
is a growth factor for bone. Since GK rats are not obese, dietary restriction 
would lead to under-nutrition, and thereby impair bone formation. 
Anesthesia and euthanasia Anesthesia for in-vivo investigations was 
performed with intraperitoneal injection of Hypnorm®. For 
immunohistochemistry, animals underwent in-vivo perfusion fixation 
through the left heart, under sodium-pentobarbitone anesthesia, then 
killed for sample collection. For all other methods, they were killed by 
decapitation under pentobarbitone overdose. 
Ethics All animal experiments were performed with approval from the 
Ethics Committee for Animal Research (North Stockholm, Sweden). 
Animals were euthanized in accordance with the guidelines of the Central 
Animal Research Committee90. 
Body Weight This variable was considered to permit valid conclusions of 
bone data. As can be seen from Table 1 the diabetic rats exhibited a lower 
body weight compared to controls. This difference between diabetic and 
Wistar rats was more pronounced in the older group of male rats than the 
younger group of female rats. These data were taken into account in the 
analysis of different bone features. 
Table 1. Body weight expressed as mean (g) ± SD. 
 Control Diabetes Difference (p-value) 
12 month (n=26+23) 
 294 ± 32  268 ± 23  -9% (0.002) 
20 month (n=10+10) 
 645 ± 103  454 ± 31  -30% (<0.001) 
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Diabetes To assess the diabetic status of the GK-rats, an intraperitoneal 
(i.p.) glucose tolerance test was done85. The animals were fasted overnight 
and fasting glucose was measured in tail blood. An i.p. injection of glucose 
solution (2g/kg body weight) was given, then blood glucose was measured 
after 30 and 120 min of glucose injection. Glucose levels were determined 
using a portable blood glucose analyzer (Accutrend®, Boehringer 
Mannheim, Mannheim, Germany). Both 12 and 20 months diabetic rats as 
well as Wistar rats were included in the test. As can be seen from Fig 2, the 
diabetic rats had significantly higher blood glucose levels confirming the 
presence of diabetes. 
Figure 2. Glucose tolerance test 
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Neuropathy In both 12 and 20 months old diabetic rats as well as Wistar 
rats nerve conduction velocity (NCV) was determined The rats were 
anesthetised with an intraperitoneal Hypnorm® (Janssen, Beerse, 
Belgium) injection (0.5 ml/kg bw). Sciatic NCV was measured using 
Neuropack 2 Evoked Potential Measuring System (Nihon Kohden 
Corporation, Tokyo, Japan), employing needle electrodes. The nerve was 
stimulated at the sciatic notch, while recording was made from the hind-
paw. The distance between the stimulating and recording electrode, and 
the latency between the electrical stimulation and the first observed action 
potential were used to determine nerve conduction velocity. Table 2 shows 
that the mean NCV was reduced in the diabetic rats.  
 
Table 2. Nerve conduction velocity results from 12- and 20- 
month old rats expressed as mean ± standard deviation. 
 Control 
n=36 
Diabetes 
n=33 
Difference (p-value) 
12 month  70.9 ± 4.3  59.1 ± 2.9  -16.7%  (<0.001) 
20 month  61.8 ± 4.9  49.8 ± 5.1  -24.1%  (<0.001) 
 
 
TISSUES 
The study focused on bone and joints using a variety of different in-vivo 
and ex-vivo methods. The radiologic investigations were applied to the 
whole skeleton, but also to individual bones, i.e. humerus, tibia, 3rd 
metatarsal and the lumbar vertebrae (L4-5). The same individual bones 
were also subjected to ash weight determinations. Immunohistochemistry 
for neuropeptides was applied to tibia, ankle, spinal cord and dorsal root 
ganglia. Immunoassays for tissue concentrations of neuropeptides were 
applied to separate samples of periosteum, bone marrow and cortical bone 
from femur and tibia, and also to whole ankle joints, dorsal root ganglia 
and spinal cord (L2-5). Preparations of cortical bone from femur were also 
made for immunoassay of IGF-I. Finally, blood samples were taken for 
determining the concentration of glucose, insulin, IGF-I and IGFBP-1 and 
IGFBP-4.  
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METHODS 
RADIOGRAPHY 
X-rays of the tibia and humerus were taken under Hypnorm® anaesthesia. 
A Siemens dental X-ray machine (Heliodent DS, Siemens AG, Bensheim, 
Germany) was used. It has a 70 micron focal spot, and fixed power and 
voltage at 7mA and 60 kV, respectively. Dental radiographic films of size 
8.5 x 5.4 cm from Kodak (Ektaspeed Plus, Eastman Kodak, Rochester, NY, 
USA) were used. After a series of trials, it was possible to achieve an 
optimum X-ray image with a 33% magnification by keeping the film 25 cm 
away from the rat and the rat 75 cm away from the X-ray source with the 
use of a specially designed platform. With this configuration, an exposure 
time of 1.25 sec proved adequate. Lateral X-rays of the limbs were taken, X-
rays were developed and then digitized using a HP Scanjet II scanner 
(Hewlett-Packard, Singapore). Scanned images were printed at a 
magnification of 20X and the outer (periosteal) diameter and the inner 
(endosteal) diameter of the bone were measured in the distal third of the 
diaphysis with a precision caliper. Cortical thickness and cortical thickness 
index were calculated as follows: 
Cortical thickness: 
2
InnerOuter −
 Cortical thickness index: 
Inner
Outer
  
Two observers independently made the measurements, from which the 
mean was calculated. The correlation between two observers was R=0.65 
and inter-observer variation was 9%. 
DEXA 
Analysis of bone mineral content and density was done using dual energy 
X-ray absorptiometry (DEXA). This method has previously been validated 
for assessment of bone mineral content in rats91,92. DEXA was done in-vivo 
on rats from which bone samples were to be processed for neuropeptide and 
IGF-I assays, while in the remaining it was done ex-vivo. The in-vivo 
analysis was done under Hypnorm® anaesthesia in a fan beam X-ray bone 
densitometer (QDR 4500A, Hologic, Bedford, MA, USA) at the Department 
of Radiology, Karolinska Hospital, Stockholm. The machine was calibrated 
daily with a phantom provided by the manufacturer. Whole body scans and 
regional high-resolution scans of the humerus, lumbar vertebrae L4 and L5 
and the tibia were performed.  
The software permits analysis of defined regions within the bones. Hence, 
for humerus and tibia, the metaphysis and diaphysis were analysed 
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separately. For tibia, the sub-regions included the metaphysis in the 
proximal 15% of the bone length and the diaphysis in the distal 15%. For 
humerus, the corresponding sub-regions were proximal 20% and middle 
15%. The vertebrae L4 and L5 were analysed together as a whole. Analysis 
provided projected bone area in cm2, bone mineral content (BMC) in grams 
and areal bone mineral density (a-BMD) in grams per cm2.  
For ex-vivo analysis, the rats were killed by decapitation under anaesthesia 
with Hypnorm®. The lumbar vertebrae including part of the pelvis, whole 
humerus, tibia and 3rd metatarsal bones were dissected, cleared of soft tissue 
and stored in 70% ethanol. A high-resolution peripheral DEXA (pDEXA) 
machine was used (pDEXA Sabre, Norland, Fort Atkinson, WI, USA)93. This 
machine, as well as the pQCT machine (see below), are located in the animal 
laboratory of the Department of Endocrinology, Sahlgrenska University 
Hospital, Gothenburg, Sweden. It is calibrated daily with a phantom 
provided by the manufacturer. Bones were placed in a petri-dish containing 
a 15 mm layer of 70% ethanol. Medium-resolution scans were taken with the 
settings at line spacing 0.5 mm, speed 15 mm/sec and histogram averaging 
width 0.2 g/cm2. The length of the bones was measured using the software’s 
ruler tool, which has a precision of 0.1 mm. Sub-region selections were done 
in the same way as for ex-vivo DEXA. Bone area, BMC and BMD were 
obtained for whole bones and the sub-regions described.  
The inter-scan coefficient of variation (CV) for the DEXA measurements 
was 3-5%, as assessed by scanning bones five times after repositioning. 
PQCT 
Tomographic measurements of the same post-mortem specimens were 
made using the Stratec XCT Research M (Norland, Fort Atkinson, WI, 
USA), which has a voxel resolution of 70 microns, and software specifically 
modified for use on small bone specimens (version 5.40B, Stratec)94.  
The bones were placed in plastic tubes filled with 70% ethanol. For 
trabecular bone analysis of the long bones, they were scanned at the 
proximal metaphysis. To determine the most suitable level a series of scans 
was performed at different distances from the proximal growth plate line. A 
distance equal to 4% of the whole bone length for tibia and 15% for 
humerus was chosen, considering the amount of trabecular bone. These 
sites, well within the metaphysis, were chosen for trabecular BMD 
analysis. In the metatarsal, no metaphyseal scan was taken for technical 
reasons because of the small size of the bone and very short metaphysis. In 
the spine, a series of scans was done on the L4 and L5 vertebral bodies, and 
two levels were chosen; the mid-portion (50% of vertebral body height) and 
near the distal end-plate (85% of height) (Fig.3). 
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Figure 3 A-D. pQCT 
PQCT pictures from proximal tibia (A,B) and vertebral bodies (C,D) from control 
(A,C) and diabetic (B,D) rats. Lower BMD in the trabecular regions can be 
observed in diabetic rats. H=high BMD, L=low BMD 
For identifying trabecular bone the area protocol was selected, which 
defines trabecular bone as that lying within the inner 45% of the cross 
sectional area. This protocol is a standard in the CT software and a 
convention applied by others95,96. Analysis gave the cross-sectional area in 
mm2 and volumetric BMD (v-BMD) in g/cm3 for the whole cross-section as 
well as separately for the trabecular bone. For cortical bone analysis of 
diaphyseal bone, the humerus was scanned at 70% of its length from the 
proximal end, the tibia at 75% from the proximal end, and the metatarsal 
in its middle. These positions were chosen because they lie within the 
cylindrical portions of the bones, where variations in bone dimension due to 
positioning are minimal. 
For identifying cortical bone, the software uses density thresholding and 
calculates periosteal and endosteal diameters based on the “circular ring 
A B 
 
 
 
 
 
 
 
 
C D 
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model”97. Analysis provides volumetric cortical BMD in g/cm3, cortical 
thickness in mm, periosteal and endosteal circumferences in mm, and 
cross-sectional moment of inertia in mm4, the latter an estimate of bending 
strength. The bending strength and/or stiffness of long bones is related to 
both cross-sectional moment of inertia and Young's elastic modulus98. The 
former indicates the architectural fitness and depends on the external 
diameters of bone cross section, while the latter represents bone material 
stiffness and is related to tissue ash weight content per dry weight, i.e. 
BMD. 
The inter-assay coefficients of variation (CV) for the pQCT measurements, 
assessed previously in our laboratory by scanning bones five times after 
repositioning, was less than 2%. 
Comments When analyzing bone size and form, DEXA and pQCT analyses 
offer different information. DEXA software provides 2-dimensional data 
from X-ray images, based on the X-ray absorption characteristics of 
mineralized tissues. It is able to assess the size of the whole skeleton and of 
individual bones in terms of projected area. Also, within individual bones 
analysis of sub-regions is possible by defining of regions of interest from the 
software99. The main use of DEXA is in the assessment of areal BMD. The 
software calculates a-BMD by dividing the BMC with the bone area. Many 
studies have shown good correlation between a-BMD measurements from 
DEXA and bone strength as well as fracture risk100. It has now become a 
fairly routine procedure in the clinical setting for evaluation of osteoporosis 
and response to therapy18. 
In contrast to DEXA, pQCT offers 3-dimensional information. It is based on 
cross-sectional slices with a pre-determined volume. It determines BMC 
from tomographic data, and calculates BMD by dividing the content with 
the volume of bone. The BMD thus obtained is mineral per unit volume of 
bone, representing volumetric “true” BMD. pQCT permits the assessment 
of circumferential morphology and is able to distinguish between cortical 
and trabecular bone93. It has been validated against histomorphometrical 
analysis of trabecular and cortical bone101-103. 
ASH WEIGHT 
Ash weight analysis is used as a gold standard to validate BMC 
measurements by DEXA104. After the DEXA and pQCT analyses, the post-
mortem specimens were defatted in acetone for 48 hours and desiccated at 
60ºC for 72 hours. Defatted dry weight of the bones was measured. The long 
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bones were divided into metaphyseal and diaphyseal portions, 
corresponding roughly to the sub-regions selected in DEXA software. The 
vertebrae L4 and L5 were disarticulated from the rest of the spine. Each 
bone and segment of bone was weighed, incinerated at 700ºC in a muffle 
furnace (MR 170, Axel Kistner, Stockholm, Sweden), and then ash weight 
(mg) was determined reflecting mineral content. The sum of ash weights of 
the segments of each bone gives the total mineral content of that bone. 
When ash weight is divided by the dry defatted weight, it indicates the 
proportion of the dry weight of the bone that is mineral as opposed to 
matrix. This percent ash is another estimate of mineral density. 
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) was done for morphological analysis of nerve 
fiber occurrence and distribution according to specific neuropeptides in 
bone and joint tissue. 
The rats were anesthetized with Hypnorm® and perfused through the left 
heart with phosphate-buffered saline (PBS) while being exsanguinated 
through the right atrium, until the effluent from the atrium was nearly 
clear of blood (approx 300 ml PBS). Perfusion fixation was then done with 
Zamboni's fixative (4% paraformaldehyde with picric acid)105 until the 
extremities became yellow and stiff (approx 300 ml).  
The tibial diaphysis, ankles, the L2-L5 segment of the spinal cord and the 
corresponding dorsal root ganglia were dissected. Samples were stored in 
Zamboni's fixative for post-perfusion fixation for 6-8 hours, then the soft 
tissue samples were placed in buffered 20% sucrose while the skeletal 
samples were demineralized in 4% buffered EDTA solution106. Twice 
weekly exchanges of the solution were done for a period of approx. 4-6 
weeks, until adequate demineralization was confirmed by passing a needle 
through different parts of the bones, then the samples were placed in 20% 
sucrose. After having been at least 48 hours in sucrose, the samples were 
embedded in Tissue-Tek® O.C.T. compound (Sakura Finetek, the 
Netherlands). Frozen sections were made on a Leitz® 1720 cryostat (Ernst 
Leitz, Wetzlar, Germany) at 15 µm thickness and transferred onto 
SuperFrost® Plus glass slides (Menzel-Glaser, Freiberg, Germany).  
The slides were stained according to the avidin/biotin system of 
immunostaining. Commercially available polyclonal antibodies against two 
sensory neuropeptides i.e. substance P (SP) and calcitonin gene-related 
peptide (CGRP), and one autonomic i.e. neuropeptide Y (NPY) (Peninsula 
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Labs., St. Helens, UK) were applied to the sections and incubated 
overnight. The SP antibodies cross-react with neurokinin A (40%), but not 
with endothelin 1. The CGRP antibodies cross-react with rat CGRP II 
(79%) but not with amylin, calcitonin or somatostatin. The NPY antibody 
does not cross react with PYY, pancreatic polypeptide, VIP, amylin, insulin 
or somatostatin. The dilutions were 1:10000 for SP and CGRP, and 1:5000 
for NPY antiserum. Incubation was then done with biotinylated secondary 
antibodies for 40 minutes. Finally, the bound secondary antibodies were 
labeled with the fluorochrome Cyanine-2 (Cy-2) -conjugated avidin 
(Amersham Biosciences, Uppsala, Sweden) diluted 1:2000, during 40 
minute incubation. Control staining was performed by omitting the 
primary antibody.  
The slides were mounted with cover slips using glycerol gelatin and 
visualized under an epifluorescence microscope (Eclipse E800, Nikon, 
Tokyo, Japan) connected to a computer via a Nikon DXM1200 digital video 
camera. 
RIA - NEUROPEPTIDES 
Quantitation of neuropeptides in tissue extracts was done by RIA. Under 
Hypnorm® anesthesia, the animals were decapitated and blood was 
collected, centrifuged and serum was frozen. Both ankles were dissected 
and crushed. From the diaphyses of both femora and tibiae, the periosteum, 
bone marrow and cortical bone were collected. The periosteum was scraped 
off from the bone, the marrow was pushed out from the medullary canal 
and the remaining cortical bone was crushed. The lumbar spinal cord and 
dorsal root ganglia were also collected, as mentioned for 
immunohistochemistry. Wet weight of the samples was measured using a 
precision balance. Samples were frozen in a box of dry ice and subsequently 
stored in a –70ºC freezer. Throughout dissection samples were kept on 
petri-dishes containing ice. 
Extraction from the frozen samples was done by boiling the soft tissues in 
1M acetic acid and skeletal tissues in 2M acetic acid in 4%EDTA for 10 
minutes107,108. Samples were homogenized with Polytron® and sonicated, 
then centrifuged at 3,000 RPM for 15 min at 4ºC. The supernatant was 
frozen at –70ºC and subsequently lyophilized. 
Samples for neuropeptide analysis were reconstituted in phosphate buffer 
and assayed by competitive radioimmunoassay. The samples and standard 
peptides were incubated with rabbit antibodies directed against SP and 
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CGRP (courtesy Prof. E. Theodorson, Linköping University, Sweden)109 and 
NPY (Phoenix, CA, USA) for 48 hours at 4ºC. The SP antibodies cross-react 
with SP sulfoxide, but not with other tachykinins. The CGRP antibodies 
cross-react with CGRP α (93%) and β (24%), but negligibly (<0.01%) with 
SP, NPY and other peptides. The NPY antibodies cross-react with PYY 
(100%) but not with VIP, amylin, insulin or somatostatin. Radioiodine 
(131I)-labeled peptide was added and incubation done for 20-24 hrs.  
To separate the bound and unbound radioligand, Sac-Cel® (Wellcome 
Diagnostics/IDS, Boldon, England) for SP and CGRP and decanting 
Suspension-3 (Pharmacia and Upjohn Diagnostics, Uppsala, Sweden) for 
NPY were added. The reaction was stopped after 30 minutes by adding 
distilled water, tubes were centrifuged at 6-8ºC at 3500 RPM for 15 min, 
and the supernatant containing the unbound radioligand was decanted.  
The radioactivity in the residual pellets was measured using a gamma 
counter (Wallac Inc., Turku, Finland). The concentrations of neuropeptides 
in pmol/L of the sample preparation were calculated by the Gamma 
counter’s computer software. The detection limit for SP was 3.9 pmol/L and 
for CGRP and NPY it was 7.8 pmol/L. The average intra-assay CV was 
10%. 
CHARACTERIZATION 
To characterize the immunoreactivity obtained by RIA, reverse phase high 
performance liquid chromatography (HPLC) was done. HPLC equipment 
(Gilson, Villiers-le-Bel, France) and a Waters Delta Pak (C18, 300 Å) 3.9 
mm x 150 mm column were utilized.  
The samples were filtered using Millipore GS filters (0.45 µm) and 200 µl of 
each sample was injected into the column. Samples were eluted with a 40 
min linear gradient of acetonitrile in water containing 0.1% trifluoroacetic 
acid and fractions of 0.5 ml collected at a rate of 1.0 ml/min. A gradient of 
10-60% was used for SP and CGRP, and 20-70% for NPY. The fractions 
were lyophilized, reconstituted in 100 µl of distilled water then assayed by 
RIA (Fig.4). A peak was observed indicating the fraction containing the 
ligand to which the RIA antibody was bound. In separate runs, control 
peptides (8000 pmol/L) were also analysed in the same way as the samples. 
METHODS   
20  
The peaks from the control peptides were found to elute in the same 
fractions as the samples. The elution fraction containing the main 
immunoreactive peak of each neuropeptide corresponded to that of the 
synthetic peptide, confirming the specificity of the immunodetection and 
the integrity of the neuropeptide of interest. 
Figure 4. HPLC 
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IMMUNOASSAYS – IGF-I AND IGFBPS 
Quantitation of IGF-I, IGFBP-1 and IGFBP-4 and insulin in serum, and 
IGF-I in tissue extracts was done by immunoassays.  
Serum IGF-I concentrations were determined by RIA after acid ethanol 
extraction and cryoprecipitation, and using truncated IGF-I as tracer, 
based on the method of Bang et.al.110. The intra- and inter-assay variation 
was 4% and 11%, respectively. 
IGFBP-1 concentrations were measured using a plate immunoassay 
described in a previous study111. The intra- and inter-assay variation was 
5% and 15%, respectively. 
IGFBP-4 was measured by RIA at the laboratory of Growth and 
Development, California Pacific Medical Center Research Institute, San 
Francisco, CA, USA according to the method of Chelius et.al112. Serum 
IGFBP-4 levels in control rats from the current project have been reported 
by Chelsius. The intra- and inter- assay variation was 3% and 8%, 
respectively. 
Serum insulin was measured using a commercial rat insulin RIA kit (Linco 
Research, St. Charles, MO, USA). The intra- and inter- assay variation was 
6% and 8%, respectively. 
STATISTICS 
Variables were summarized according to mean and standard deviation. 
Parametric tests (Student’s t-test and ANOVA) were used for all group 
comparisons except when data was skewed, whereby Mann-Whitney test 
was applied. Pearson’s test was used for correlations. Effect of variability of 
body weight on the bone parameters was analysed by test of covariance 
(ANCOVA) and correlation. An α-level of 5 percent was chosen. Results are 
presented as histograms; raw data is also included in tabular form in the 
Appendix A. In histograms, the level of significance is indicated as 
*=p<0.05, **=p<0.01. ***=p<0.001. 
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SKELETAL FEATURES 
PAPER I,II 
SIZE AND FORM 
In the 12-month-old diabetic rats, the length of humerus and height of 
vertebrae were reduced by 8%, whereas the length of tibia and metatarsal 
was not (Fig.5). In fact, the latter was longer though marginally (2.9%). The 
tibial length at 20 months was greater than at 12 months in both diabetic 
and control rats. GK rats are known to grow less than Wistar rats85. From 
the current results it appears that in diabetic rats, bone size is decreased 
only in the axial and upper limb bones, while the hind limb bones are 
unaffected. Since the hind- and fore-limbs face different loading forces, the 
difference in length may indicate a change of the normal response of the 
growth plate to load in diabetic rats. The data does not support an overall 
impairment of bone growth as the tibia and metatarsal were not shorter. 
Thus, diabetes results in shortening of certain bones, apparently depending 
on load. The greater tibial length at 20 months compared to 12 months in 
both diabetic and control rats should be related to both age and sex. Growth 
probably occurred between 12 and 20 months, since rats are known to have 
partially open epiphyses at 12 months113-116. Moreover, in Wistar rats, 
males grow more than females, like most other rat strains. 
According to regional pQCT, the diaphysis of long bones in diabetic rats 
expanded (Fig.6). In fact, both the periosteal and endosteal circumferences 
were increased, the latter reflecting endosteal erosion. The cortical 
thickness at 12 months was increased in the tibia, but normal in other 
bones. At 20 months, it was normal in the tibia, but reduced in the 
metatarsal. The observed, periosteal expansion can be expected to increase 
mechanical strength, since the cortex is placed further away from the 
center of the bone117. This can occur even in the presence of endosteal 
erosion causing reduction of cortical thickness, unless the latter is very 
extensive118. Endosteal erosion and periosteal expansion are normal 
features of long bone diaphyses in aging humans eventually resulting in 
cortical thinning. In the metatarsal of diabetic rats, cortical thinning was 
observed at 20 months (appendix A, table 17). Thus, it appears that age-
related changes in diaphyseal bone occur earlier in diabetes. 
In diabetic rats, the metaphyses unlike the diaphyses showed a decrease in 
the cross-sectional area both in the humerus and tibia, albeit it was significant 
only in the latter (Fig.7). In the vertebrae, no significant difference was seen. A 
narrower metaphysis suggests mechanical weakness. The changes were seen 
in both age groups, which were also of different gender. 
Altogether, the changes observed in size and form of metaphysis and 
diaphysis seem to be consistent features of the diabetic rat skeleton. 
  Size and Form 
  23 
Figure 5. Height and length 
 
Figure 6. Circumference of diaphyses 
 
Figure 7. Cross-sectional area – vertebrae and metaphyses 
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BMC 
DEXA showed that whole body BMC was reduced in the diabetic rats by 9% 
(Fig.8). As for individual bones, a decrease was observed in all bones except 
the metatarsal. Since BMC is known to correlate with body weight and the 
diabetic rats weighed 8.7% less than controls, the lower BMC may be 
explained by the difference in body weight. Although the lower whole body 
BMC may be attributed to a smaller skeleton, a reduction in bone length 
was only observed in the humerus and vertebrae, not in the hind limb. 
Thus, the decrease in BMC despite normal length appears to indicate an 
absolute loss of mineral. The fact that the metatarsal did not exhibit loss of 
BMC should be explained by the predominantly cortical nature of the bone. 
As for regional changes, the metaphysis of all long bones showed a 
substantial reduction in BMC (Fig.9). The diaphysis, on the other hand, 
showed a significant though small increase in BMC in tibia and metatarsal, 
but a decrease in the humerus. Most of the reduction in whole long bone 
BMC should be attributed to metaphyseal bone loss. The decrease in 
metaphyseal BMC along with an increase in diaphyseal BMC may 
represent a redistribution of mineral from the trabecular to the cortical 
portion of the diabetic rat bones. The increased BMC in diaphyseal bone 
presumably increases strength. 
The DEXA results were corroborated by strong correlation with ash weight 
results (appendix A, tables 12 and 13) 
BMD 
According to DEXA, the areal BMD of the whole body was normal in 
diabetic rats. Among individual bones, a-BMD was either normal or 
reduced (Fig.10). The greatest reduction of a-BMD was observed in the 
vertebrae, the least in the metatarsals. It appears that differences in the 
relative distribution of the trabecular and cortical components within 
individual bones are responsible for the difference observed in a-BMD. 
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Figure 8. BMC 
 
Figure 9. Regional BMC 
 
Figure 10. Areal BMD – whole bone 
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As for regional changes, there was a reduction of a-BMD in the metaphysis 
of tibia and humerus in the diabetic rats, while the diaphysis of all bones 
had normal a-BMD (Fig.11). The metatarsal showed a reduction in a-BMD 
in the metaphysis at 20 months, but not at 12 months. The results imply 
that the reduction of a-BMD predominantly pertains to sub-regions 
normally rich in trabecular bone. Notably, the vertebrae also exhibited 
reduced a-BMD, as shown before. In both diabetic and control rats, the 
metaphyseal and diaphyseal a-BMD of the tibia, was lower at 20 months as 
compared to 12 months. However, in the diabetic rats, it appears that the 
reduction of metaphyseal a-BMD progresses with age. 
According to pQCT of cross-sections, the “true” v-BMD in diaphyseal bone 
was only reduced in humerus (Fig.12). In the tibia and metatarsal, there 
was no significant difference, which applied to both age groups. The lower 
v-BMD in humerus in diabetic rats may be explained by the fact that it 
bears less load than the other bones. It is conceivable that bone turn-over in 
response to loading forces is altered in diabetes. In the hind limb bones, 
which bear more load, the v-BMD was normal in diabetic rats. In both the 
diabetic and control rats, v-BMD in humerus was higher compared to tibia 
and metatarsal, which may be a normal feature of the rat skeleton. 
In regions normally rich in trabecular bone, i.e. the metaphyses of long 
bones and the vertebrae, there was a substantial reduction of v-BMD 
(Fig.13). The total v-BMD of the cross-sections, representing an average 
from cortical, sub-cortical and trabecular bone, was significantly reduced 
(range –13 to –24%) in all bones except tibia, where a tendency (p=0.065) to 
lower (–10%) v-BMD was noted. Analysis of the trabecular compartments 
showed lower v-BMD in all bones, ranging from –33 to –62%. 
The pQCT software is not able to separately provide cortical v-BMD in 
these regions, though trabecular v-BMD can be obtained. The decrease in 
trabecular v-BMD was proportionately greater than that in the total v-
BMD of the cross-section. This implies that most of the reduction of v-BMD 
observed in these regions should be ascribed to trabecular bone. 
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Figure 11. Regional areal BMD 
 
Figure 12. Volumetric BMD – Diaphysis 
Figure 13. Volumetric BMD – Vertebrae and metaphysis 
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Ash density Determination of percent ash was done to assess the 
proportion of mineral per weight of bone. The analysis showed that there 
was no change in humerus and vertebrae, while in the tibia a substantial 
reduction of percent ash was observed in the diabetic rats, most pronounced 
in the metaphysis (Fig.14). The reduction was greater in the 20-month-old 
diabetic rats. 
The finding that there was no reduction in ash density in humeral 
metaphysis and vertebrae seemingly contradicts the reduced BMD assessed 
by DEXA and pQCT in these bones. The discrepancy can be explained by 
the methodology. A lower a-BMD and v-BMD would be seen if there was an 
absolute decrease of the number of bone trabeculae. However, percent ash 
should be normal as long as the mineral density within the trabeculae is 
normal. On the other hand, a reduction in mineral density within the 
trabeculae should lower the percent ash. Thus, in humerus the decrease of 
BMD probably reflects a decrease in the number of trabeculae while in 
tibia, a decrease of both number of trabeculae and their mineral density. 
STRENGTH 
The estimate of diaphyseal strength obtained from pQCT data, i.e. the 
cross-sectional moment of inertia, showed an increase in all long bones in 
the diabetic rats, suggesting a greater bending strength (Fig 15). The 
moment of inertia is highly dependent on the periosteal diameter and the 
cortical thickness. Thus, the greater moment of inertia should be attributed 
to the diaphyseal expansion in diabetic rats. Notably, this index is based on 
cortical dimensions and does not take into account bone matrix properties, 
microstructure, BMC or BMD. As the volumetric BMD in diaphyseal bones 
was nearly normal and the BMC was increased, the increased moment of 
inertia probably represents a true increase in strength. However, for the 
bone as a whole this may well be offset by a decrease in strength because of 
osteopenia and narrowing of the metaphysis. Conceivably, periosteal 
expansion reflects an attempt to regain bone strength lost by endosteal 
erosion of the diaphysis and also osteopenia and narrowing of the 
metaphysis. The latter is supported by the apparent “redistribution” of 
BMC from the metaphysis to the diaphysis, as suggested before. Notably, 
diaphyseal fracture is not a typical feature of diabetes119 as opposed to 
periarticular fractures and Charcot arthropathy52, which may be explained 
by the metaphyseal loss of trabecular bone. 
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Figure 14. Percent ash 
 
Figure 15. Cross-sectional moment of inertia 
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COMMENTS 
The above data shows that the typical features of the diabetic rat skeleton 
are trabecular osteopenia in vertebrae and long bones metaphyses, and 
also endosteal erosion and periosteal expansion of diaphyses. The 
literature suggests that metaphyseal osteopenia is also a typical feature of 
human diabetes. Thus, metaphyseal fractures of the proximal humerus 
have been noted to occur more frequently in the diabetic population even 
after correction for age, body mass index and differences in BMD7. 
Recently, a multi-center study of patients sustaining distal radius 
fractures6 reported that the risk of intra-articular fracture was increased 
two-fold in diabetics, but not that of extra-articular fractures. A pQCT 
study examining metaphyseal bone in diabetic patients demonstrated a 
significant reduction of trabecular BMD (Z-score) of the distal radius120. 
Presumably, the clinical implication is greater risk of metaphyseal, juxta-
articular and intra-articular fractures in diabetes. These reports support 
our findings, and reinforce the notion that the bone weakness in diabetes 
pertains not to the diaphyses of long bones, but to the regions normally 
rich in trabecular bone. Osteopenia has been suggested as one of the 
factors behind the development of Charcot joint10,121. Trabecular 
osteopenia in the metaphysis presumably predisposes to subchondral bone 
collapse. Notably, increased levels of markers of osteoclastic bone 
resorption have been found in Charcot arthropathy122. 
In a previous study on the femur in streptozotocin-induced type-1 diabetic 
rats, a significant reduction of bone growth was noted along with 
metaphyseal osteopenia. Interestingly, diaphyseal BMD was greater than 
“expected” considering the decreased bone growth. However, the study 
utilised single-photon absorptiometry and no assessment of diaphyseal 
dimensions was done. Thus, the higher BMD may well have been due to 
diaphyseal expansion, considering the results of the present study. 
The regional differences in bone dimensions and mineral content prompt a 
reassessment of the methodology to be used for detection of diabetic 
osteopathy. If the v-BMD of two bones is equal, their a-BMD may not be 
equal if their outer dimensions are different24. Notably, conventional 
scanning protocols for DEXA do not consider variations in bone 
dimensions while calculating BMD. In a recent editorial123 on fractures in 
diabetes it was stated that “…a normal bone mass, as conventionally 
assessed by DXA and related modalities, can be offset by bone fragility at 
certain fracture sites and the likelihood of injury to these sites.” DEXA, the 
most commonly used method for bone mineral evaluation, cannot 
adequately determine trabecular osteopenia, nor cortical expansion. Thus, 
pQCT may be the method of choice for the assessment of diabetic 
osteopathy. 
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It may be questioned whether the changes observed in the humerus and 
vertebrae are due to decreased bone size and/or the difference in body 
weight. However, no correlation was found between bone length on one 
hand, and v-BMD and cortical dimensions on the other. Moreover, the 
changes remained significant despite correction for differences in bone 
length and body weight according to analysis of covariance (data not 
shown). Furthermore, the magnitude of the decrease in the trabecular v-
BMD was much greater than the reduction in length. Trabecular 
osteopenia is unlikely to be due to a smaller bone because v-BMD is not 
affected by differences in bone size. This is one of the main advantages of 
BMD assessments by QCT as compared to DEXA24. As for cortical 
dimensions, a reduction of length should be accompanied by a reduction in 
the periosteal circumference, but the opposite was observed in the diabetic 
rats. 
Our data shows that bone changes in diabetic rats are specific to bone and 
sub-region. This implies that local factors may be more important than 
systemic calcium regulating hormones in the pathogenesis of diabetic 
osteopathy. A variety of local factors are known to regulate local bone 
turn-over124, including prostaglandins, cytokines, growth factors and 
neuropeptides. Given the skeletal findings in diabetic rats with 
neuropathy, the subsequent investigations focused on the insulin-like 
growth factor (IGF) system and sensory as well as autonomic 
neuropeptides in bone and joints. 
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IGF SYSTEM 
PAPER III 
Analysis of insulin, IGF-I and IGFBPs in 12-month-old diabetic and 
control rats was done in serum, while IGF-I was also analysed in samples 
from ankles and cortical bone. 
SERUM 
Serum insulin levels in the diabetic rats were not significantly different 
from controls though it tended to be lower (Table 3). However, serum IGF-
I levels were clearly lower in diabetic rats, while IGFBP-1 and -4 levels 
were significantly higher. IGF-I is known to be a trophic factor for bone. A 
deficit may indicate a causal link to osteopenia. The increased levels of 
IGFBP-1 and -4 are expected to decrease circulating IGF-I bioavailability 
and thereby decrease the trophic effect of IGF-I on bone. 
 
BONE AND JOINT 
In diabetic rats a significant reduction of IGF-I was found in cortical bone, 
but not in ankles (Fig.16). The levels presumably reflect both endocrine as 
well as paracrine IGF-I. Regardless of the source, these local levels can be 
expected to have significance for local bone turnover. In diabetic rats, the 
local IGF-I deficiency in cortical bone presumably underlies the endosteal 
erosion observed in the diaphysis, although compensated by periosteal 
bone formation. 
 
 
Table 3. Serum insulin, IGF-I and IGFBP levels 
(mean ng/ml ± SEM).  
 Control Diabetes Difference (p-value)  
Insulin  1.6 ± 0.5  1.1 ± 0.3  -30.7% (0.463)a 
IGF-I  205 ± 50  168 ± 26  -18.0% (0.009) b 
IGFBP-1  21 ± 5  39 ± 32  89.2% (<0.001)a 
IGFBP-4  422 ± 53  505 ± 71  19.7% (<0.001) b 
a,b: p-value according to Mann-Whitney U test (a) and T-test (b). 
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Figure 16. Bone and joint IGF-I. Error bars=SEM 
 
 
 
 
 
COMMENTS 
 
The results show that the IGF system in diabetic rats with regional 
osteopathy is disturbed not only systemically, but also locally. It may 
prove that the skeletal features demonstrated in diabetic rats are related 
to this disturbance. In insulin deficiency of human type-1 diabetes, serum 
IGF-I is decreased, while IGFBP-1 is increased. These observations are in 
line with the results of the current study. Moreover, the lower IGF-I and 
higher IGFBPs in the serum in the diabetic rats comply with lower whole 
body BMC, also with lower metaphyseal BMC and BMD, as would be 
expected from reduced IGF-I activity. In cortical bone, the IGF-I level may 
be assumed to reflect both endocrine and paracrine IGF-I. The decrease 
observed implies that the anabolic effect of IGF-I on bone cells is reduced. 
The diaphyseal findings in diabetic rats may appear to speak against the 
probable effect of decreased systemic and local IGF-I levels considering 
the expansion of the humeral and tibial diaphyses. However, the main 
effect of IGF deficit is probably endosteal erosion, eliciting a compensatory 
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periosteal expansion in response to load. The metaphyseal decrease in 
BMC, presumably caused by low IGF-I, and the concomitant increase in 
diaphyseal BMC possibly reflect a redistribution of mineral. Given that 
both systemic and local IGF-I deficit in diabetes leads to bone loss, it 
appears that the response to this loss decisively differs between trabecular 
and cortical bone. While cortical bone responds to the endosteal erosion by 
periosteal bone formation, trabecular bone in the metaphyses does not 
seem to have this compensatory mechanism. It may prove that the 
adverse effect of the disturbed IGF-system in diabetes is confined to the 
inner surfaces of bone, whereas the outer escape from major loss by 
compensatory mechanisms. In the elderly population, metaphyseal 
osteopenia and cortical expansion are also seen26 concomitantly with a 
decline in serum IGF-I levels. Thus, the bone changes observed in the 
diabetic rats seem to mimic early bone aging.  
Considering that in diabetic rats, IGF-I levels were reduced in both serum 
and cortical bone, it was unexpected to find normal IGF-I level in ankles. 
Possibly, this can be explained by a high contribution of local IGF-I levels 
in non-osseous tissues of the ankle, such as cartilage, synovium, 
ligaments, tendons, surrounding blood vessels and areolar tissue. 
As for the higher IGFBP-1 and -4 levels in diabetic rats, they comply with 
decreased BMD, since both have an inhibitory effect on IGF-I activity and 
hence, bone formation. However, systemically administered IGFBP-4 has 
been shown to have direct bone formative effects in-vivo unlike its in-vitro 
effects125. The in vivo effect has been attributed to proteolytic fragments of 
this protein. The predominant role of paracrine IGFBP-4, however, is one 
of sequestration of IGF-I and inhibition of the latter’s action126. The 
results of the current study suggest that in diabetic rats, the relation 
between local IGF-I levels and BMD is altered. To what extent IGFBP-1 
and -4 levels influence this relationship is unclear. Other IGFBPs may 
also be of significance, especially IGFBP-5, which has been reported to act 
as a growth factor for bone44. 
In diabetic rats, relative insulin deficiency, hyperglycemia and altered 
IGFBP activity may affect the relation between IGF-I and BMD. Although 
serum insulin levels in our diabetic rats were not significantly different 
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from controls, previous studies on the GK rats have shown higher insulin 
levels in early life and lower levels in older age, as compared to age- and 
sex-matched control rats85,87. However, at all ages they exhibit a blunted 
insulin response to glucose challenge, and thus have a relative insulin 
deficiency. This deficiency may well contribute to decreased BMD 
considering that insulin is a growth factor for bone.  
It may be concluded that this is the first study demonstrating 
abnormalities of the IGF-system in rats with type-2 diabetes and regional 
osteopathy. It is also the first study on local IGF-I levels in bone. From the 
results, it appears that not only the systemic levels of IGF-I are related to 
the observed bone changes, but also the local levels. However, regional 
osteopathy in diabetes cannot be exclusively explained by IGF-I. Apart 
from its interactions with IGFBPs, and the direct effects of the latter on 
bone, there are other local factors of importance for local bone turn over. 
In addition to different factors acting independently of the IGF system in 
bone, it may prove that the diabetic complications related to IGF system 
abnormalities, such as neuropathy127, also contribute to the development 
of diabetic osteopathy. 
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NEUROPEPTIDES 
PAPER IV 
In 12-month-old diabetic and control rats the occurrence of sensory and 
autonomic neuropeptides in bone and joint as well as spinal cord and dorsal 
root ganglia was assessed by immunohistochemistry and RIA. 
MORPHOLOGY 
In both diabetic and control rats, immunohistochemical analysis showed the 
presence of sensory (SP, CGRP) and autonomic (NPY) nerve fibers in bone 
and joints (Fig. 17A-D), although in general they were quite sparse. An 
abundance of perivascular nerve fibers, both sensory and autonomic, was 
seen in the loose connective tissue, synovium and cortical bone, while non-
vascular nerves were frequently seen in the periosteum and bone marrow. 
Figure 17 A-D. 
Photomicrograph of sections through bone and jonts stained immunohistochemically for SP 
(A), CGRP (B) and NPY (C,D). Nerve fibers (arrows) positive for SP in synovium (A) and 
CGRP in periosteum (B) are shown. NPY-positive nerve fibers (C) are seen in a vascular 
channel in cortical bone. In bone marrow in tibial diaphysis (D), NPY-positive nerve fibers 
(arrows) and cells (arrow-heads) are observed. S=synovium, AC=articular cartilage, JS=joint 
space, B=bone, P=periosteum, M=muscle, BV=blood vessel, BM=bone marrow. Bar=50µ. 
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As for the distribution of sensory versus autonomic nerves, there were, 
certain differences. Thus, in the bone marrow, SP and CGRP fibers were 
only occasionally seen, and were mostly peri-vascular, while NPY-nerve 
fibers were frequently observed both vessel related and as free nerve 
terminals. Notably, cellular immunoreactivity to NPY was also observed in 
large multinucleated megakaryocytes and occasional mononuclear 
hematopoietic cells of the bone marrow. In cortical bone, NPY-nerves were 
seen in vascular canals, more frequently near the endosteal surface. In 
addition to bone and joints, the occurrence of SP and CGRP was also 
analysed in dorsal root ganglia and the spinal cord. As expected, 
immunoreactivity for both neuropeptides in GK rats as well as controls was 
found in lamina I and II of the dorsal horn and the cell bodies of the dorsal 
root ganglia. Over all, the immunoreactivities of the tissues analysed, 
besides bone marrow, were confined to neuronal structures, but no clear 
difference between diabetic rats and controls could be seen. 
TISSUE LEVELS 
RIA for SP and CGRP in bone and joints showed no significant differences 
between diabetic and control rats, although the mean values suggested an 
increase in CGRP and a decrease in SP (Table 4). The results for SP in 
periosteum and bone marrow were excluded because the values were below 
or near the detection limit (↓). 
Table 4. Tissue neuropeptide levels according to RIA (pmol/g wet weight) 
 Control (n=21) Diabetes (n=18) Difference (p-value) 
SP 
  
Bone  0.14 ± 0.11  0.08 ± 0.05  -40.4% (0.255) 
Periosteum 
  ↓   ↓   
Bone marrow 
  ↓   ↓   
Ankle  0.20 ± 0.17  0.21 ± 0.19  7.3% (0.694) 
Dorsal root ganglia  0.74 ± 0.17  0.68 ± 0.15  -7.9% (0.346) 
Spinal cord  19.2 ± 5.33  19.92 ± 5.44  3.7% (0.732) 
CGRP 
   
Bone  0.24 ± 0.11  0.30 ± 0.12  22.0% (0.243) 
Periosteum  0.21 ± 0.07  0.26 ± 0.08  19.8% (0.311) 
Bone marrow  1.64 ± 1.20  1.21 ± 0.95  -26.3% (0.132) 
Ankle  1.24 ± 0.28  1.40 ± 0.38  13.2% (0.194) 
Dorsal root ganglia  24.09 ± 5.64  17.80 ± 4.19  -26.1% (0.002) 
Spinal cord  87.06 ± 15.79  70.48 ± 15.57  -19.0% (0.010) 
NPY 
   
Bone  3.65 ± 0.88  2.33 ± 0.57  -36.2% (<0.001) 
Periosteum  1.49 ± 0.87  1.07 ± 0.54  -28.5% (0.156) 
Bone marrow  92.9 ± 46.1  31.22 ± 17.60  -66.4% (<0.001) 
Ankle  1.05 ± 0.38  0.75 ± 0.21  -28.7% (0.016) 
Spinal cord  42.01 ± 15.33  43.04 ± 9.11  2.4% (0.835) 
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The concentration of NPY in bone and joints was significantly decreased in 
diabetic rats (Table 4), in cortical bone by 36%, in bone marrow by 66% and 
in ankle by 29%. In the spinal cord and dorsal root ganglia, CGRP, but not 
SP, was significantly lower (19%, 26% respectively). 
COMMENTS 
From the results it is obvious that diabetic rats exhibit distinct peripheral 
neuropeptidergic changes in bone and joints. The most conspicuous findings 
pertained to the autonomic peptide NPY, which was substantially reduced 
in these tissues, while the sensory peptide CGRP was reduced in the spinal 
cord and dorsal root ganglia. In diabetic rats neuropathy has previously 
been described in terms of reduced nerve conduction velocity and 
morphological changes of the nerves, and lately, also in terms of 
neuropeptidergic changes in peripheral tissues such as the dorsal root 
ganglia, sciatic nerve and skin80-82. The present study, however, is the first 
report on neuropeptide occurrence in bone and joints in diabetes. The 
changes observed may prove to contribute to the development of diabetic 
osteopathy. 
Among sensory neuropeptides, SP has been found to be a potent bone 
resorptive factor62,63 and its receptor (NK-1) has been demonstrated in 
osteoblasts, osteocytes and osteoclasts67 CGRP inhibits bone resorption64 
suppresses osteoclastogenesis65 and increases osteoblast proliferation66. In 
this study, a decrease in CGRP was seen in the DRG and spinal cord, 
whereas in bone and joints the changes were insignificant. Considering the 
mild form of diabetes in these rats, the sensory neuropathy may not yet be 
advanced enough to involve bone and joint tissue. If, at a later stage the 
deficit of CGRP propagates to bone and joints, it would likely result in 
enhanced bone resorption, given the known anti-resorptive effect of CGRP. 
From our study, it appears that autonomic neuropathy is more pronounced 
than sensory. This complies with observations on diabetic patients, in 
which the onset of sub-clinical autonomic nerve dysfunction precedes that 
of sensory dysfunction128,129. Notably, a decrease of NPY but not of CGRP or 
SP, has been reported in a clinical study on forearm skin in diabetes 
patients130. The greatest deficit of NPY was found in the bone marrow. 
Since immunohistochemistry showed that several cell types in the bone 
marrow stained positive for NPY, the deficit according to RIA may reflect 
partly cellular loss and partly neuronal. However, in cortical bone and 
ankles staining was confined to nerve fibers. Thus, the loss in these tissues 
of NPY should be ascribed to neuronal tissue. 
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NPY is produced in the peripheral nervous system in sympathetic ganglia 
and is co-released with noradrenaline from sympathetic nerves. It has a 
sustained vasoconstrictory effect, confirmed also in bone129. Diabetic 
patients with autonomic neuropathy exhibit abnormalities of 
vasoregulation48. Moreover, increased bone resorption50,51 has been noted in 
the presence of abnormal vasoregulation. In the current study, most of the 
NPY-nerve fibers in cortical bone were seen in the Volkmann’s canal, 
alongside blood vessels. Moreover, most of the nerve fibers in the bone 
marrow were perivascular. The loss of NPY is therefore likely to disturb 
normal vasoregulation and thus promote bone resorption. 
Among autonomic neuropeptides, vasoactive intestinal polypeptide (VIP) 
has been shown to act on both osteoclasts as well as osteoblasts70,132. In this 
study, however, the focus was on NPY, which also has effects on bone turn-
over through a variety of central and peripheral mechanisms. In the central 
nervous system, NPY acts as a downstream mediator of leptin, and thus 
exerts an anti-osteogenic effect133. In the periphery, sympathectomy by 
surgical73 or chemical74 methods, presumably reducing NPY levels, has 
been shown to increase osteoclast number and surface. Although the 
opposite has been reported by Cherruau et.al134, there are other reports 
supporting an anabolic effect of NPY on bone. NPY attenuates the effect of 
noradrenaline on osteoblasts69. Since blockage of noradrenaline action by 
receptor antagonist results in an increase of bone mass133, it is likely that 
attenuation of noradrenaline action by NPY results in a pro-osteogenic or 
anti-resorptive effect on bone. Indirect evidence of the presence of NPY 
receptors on osteoblasts in-vitro has been reported69. 
Although specific causal mechanisms have not been elucidated in the 
present study, it is likely that decreased occurrence of NPY in bone and 
joints contributes to the development of diabetic osteopathy. 
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SUMMARY AND CONCLUSIONS 
The present study on non-obese Goto-Kakizaki (GK) rats with type-2 
diabetes and neuropathy was an attempt to describe and define pertinent 
features of diabetic osteopathy. Altogether, the study included 33 diabetic 
GK-rats aged 12 and 20 months, and 36 age-matched Wistar rats as 
controls. All underwent test of glucose tolerance and nerve (sciatic) 
conduction velocity (NCV) showing that the diabetic rats had significantly 
higher blood glucose levels and lower NCV, confirming the presence of 
diabetes and neuropathy. 
Radiologic analysis showed regional changes of the diabetic skeleton. 
Thus, the length of humerus and height of vertebrae was reduced and the 
long bones exhibited both endosteal erosion and periosteal expansion of 
the diaphyses. Bone mineral content (BMC) of the whole skeleton 
according to DEXA was significantly reduced mainly because of loss in the 
vertebrae and metaphyses of long bones. The latter regions also showed a 
significant decrease in areal bone mineral density (a-BMD), whereas no 
such decrease was seen in the diaphyses. Cross-sectional measurements 
by pQCT permitting determination of volumetric (v-) BMD and separation 
of cortical and trabecular bone showed that the decrease in v-BMD almost 
exclusively pertained to trabecular bone (vertebrae, metaphyses), whereas 
v-BMD of the cortical bone of diaphyses was only marginally affected. 
The results indicate that juxta-articular trabecular bone in diabetes is 
substantially weaker, whereas diaphyseal cortical bone may be even 
stronger. Thus, the diaphyseal expansion increased the cross-sectional 
moment of inertia, an estimate of bending strength, in the diabetic rats. 
Admittedly, this is only a calculated index based on cortical dimensions 
and does not take into consideration bone microstructure, BMC or BMD. 
However, since the volumetric BMD in diaphyseal bones was nearly 
normal and the BMC was increased, the increased moment of inertia 
probably represents a true increase in strength. Notably, virtually all 
reports on the increased risk of fracture in diabetic patients deal with 
juxta-articular fractures, not diaphyseal fractures. 
In the diabetic patient population, a screening of different bones by pQCT 
may identify the typical bone and sub-region having the most pronounced 
osteopenia as compared to controls. Routine pQCT of such a defined site 
may enable detection of early diabetic osteopathy. This could be used to 
establish the indication for preventive treatment to reduce the risk of 
fracture and development of Charcot joint. The approach may also be 
applied to diabetic patients having sustained a fracture to detect the 
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subset at increased risk of developing post-traumatic osteopenia and/or 
Charcot joint. 
From the present study, it is not possible to establish whether the skeletal 
changes in the diabetic rats are due to the metabolic disorder or genetic 
differences between the diabetic and Wistar rats. Since the diabetic rats 
are bred from Wistar rats, they are expected by virtue of the breeding 
procedure to be genetically more similar to the Wistar than any other 
strain. The type-2 diabetes in the GK-rat is likely to be polygenetic, 
similar to human type-2 diabetes. This implies that a diabetic rat cannot 
be genetically identical to a non-diabetic rat. Quite possibly, the genes 
responsible for the diabetic disorder may also affect bone. Nonetheless, it 
remains that the observations made in the diabetic rats reflect that the 
diabetic skeleton is characterized by regional changes in size, form, 
mineral content and density, and mechanical properties, which cannot be 
exclusively explained by systemic factors like calcium regulating 
hormones. Local bone turn-over is regulated by complex mechanisms 
involving cytokines, prostaglandins, growth factors and, notably, also 
neuropeptides. Given the focus in the present study on osteopathy in 
diabetes complicated by neuropathy, further analysis aimed at exploring 
the insulin-like growth factor (IGF)-system and neuronal mediators in 
bone. 
Immunoassays of IGF-I were done on serum, ankle samples and cortical 
preparations from femur and tibia. In addition, IGFBP-1 and -4 were 
analysed in serum. In diabetic rats, serum IGF-I was significantly 
reduced, whereas IGFBP-1 and -4, known to inhibit IGF-I actions, were 
significantly increased. These may underlie the metaphyseal osteopenia. 
In cortical bone, IGF-I was also significantly reduced. Thus, there was 
both a systemic and local reduction of IGF-I bioavailability. In cortical 
bone, the loss of IGF-I in diabetes represents a novel finding. Given the 
cortical expansion observed in diabetic rats, an increase in IGF-I would be 
expected. Conceivably, loss of IGF-I causes endosteal erosion which, 
however, is compensated by periosteal expansion in response to load. Our 
data suggests that the response to IGF deficit depends on the type of bone, 
i.e. cortical or trabecular. In the former, the endosteal erosion is 
compensated by periosteal expansion, maintaining cortical thickness. 
However, in trabecular bone, there is no such compensatory mechanism, 
hence an absolute osteopenia results. 
The investigation of bone and joint neuropathy entailed 
immunohistochemistry of neuropeptides applied to ankles and tibial 
diaphyses, and RIA for separate preparations of periosteum, cortex and 
bone marrow from femur and tibia and whole ankles, in addition also 
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dorsal root ganglia (DRG) and lumbar spinal cord. The analyses focused 
on two sensory mediators, i.e. substance P (SP) and calcitonin gene-
related peptide (CGRP), and one autonomic, i.e. neuropeptide Y (NPY). 
The morphological analysis showed that most immunopositive fibers were 
vessel related, although free terminals in bone and synovia were also 
observed without any discernible difference between diabetic rats and 
controls. A conspicuous finding was the abundance of NPY-positive 
megakaryocytes and mononuclear cells in bone marrow. RIA revealed a 
significant decrease of CGRP, albeit not SP, in DRG and spinal cord in the 
diabetic rats. As for bone, only NPY was significantly reduced, most 
evidently in bone marrow, but also in cortical bone and ankles. Given the 
bone anabolic effects of NPY and CGRP, the deficit of these neuropeptides 
may prove, at least partly, to underlie the loss of bone observed in diabetic 
rats. From our study, it seems that autonomic neuropathy is more 
pronounced than sensory in diabetic rats with mild to moderate diabetes, 
representing an early stage of the disease. 
Our combined findings suggest that osteopathic changes in diabetes are 
related to abnormalities of the IGF system and peripheral neuropeptide 
occurrence. However, the exact causal relationship and the specific 
mechanisms involved have yet to be elucidated. 
In summary, this is the first study to show that the skeleton of diabetic 
rats with type-2 diabetes and neuropathy is characterized by regional 
structural changes and abnormalities of IGF and neuropeptides, 
suggesting that also local factors beyond systemic play a role in the 
development of diabetic osteopathy. 
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APPENDIX A – TABULATED RESULTS 
GLUCOSE TOLERANCE TEST 
Table 5. Glucose tolerance test. Blood glucose level expressed as mean 
(mmol/L) ± SD at denoted time after glucose injection 
 Control Diabetes Difference (p-value) 
12 month  (n = 26)  (n = 23)  
Fasting 
 5.2 ± 0.9  9.1 ± 1.8  75% (0.020) 
30 min 
 15.7 ± 2.8  24.7 ± 5.2  57% (0.020) 
2 hour 
 5.7 ± 1.0  15.3 ± 3.8  169% (<0.001) 
20 month  (n = 10)  (n = 10)  
Fasting 
 3.2 ± 0.3  4.4 ± 1.3  37% (0.020) 
30 min 
 13.6 ± 6.9  21.7 ± 5.5  60% (0.014) 
2 hour 
 8.5 ± 3.7  23.7 ± 6.3  178% (<0.001) 
 
 
 
RADIOGRAPHY 
Table 6. Diaphyseal characteristics of humerus and tibia from 12- 
month-old rats according to X-ray (mean ± SD) 
 Control 
n=21 
Diabetes 
n=18 
Difference 
(p-value) 
Humerus    
Periosteal diameter (mm)  2.3 ± 0.2  2.6 ± 0.2  10.3% (<0.001) 
Endosteal diameter (mm)  0.9 ± 0.1  1.1 ± 0.1  23.2% (<0.001) 
Cortical thickness (mm)  1.5 ± 0.1  1.5 ± 0.1  2.6% (0.447) 
Cortical thickness index 
(periosteal/endosteal dia.) 
 2.7 ± 0.3  2.4 ± 0.2 -11.0% (0.003) 
Tibia    
Periosteal diameter (mm)  2.0 ± 0.2  2.2 ± 0.1  7.2% (0.004) 
Endosteal diameter (mm)  0.8 ± 0.1  0.9 ± 0.1  17.8% (<0.001) 
Cortical thickness (mm)  1.3 ± 0.1  1.3 ± 0.1  1.0% (0.747) 
Cortical thickness index 
(periosteal/endosteal dia.) 
 2.7 ± 0.2  2.5 ± 0.3  -8.9% (0.008) 
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DEXA 
Table 7.  In-vivo DEXA results from 12-month-old rats (mean ± SEM) 
 Control 
n=21 
Diabetes 
n=18 
Difference 
(p-value) 
Bone Area    
WHOLE BODY (cm2)  54.1 ± 0.9  50.7 ± 0.7  -6.3% (0.006) 
HUMERUS (mm2)    
Prox. Metaphysis  29.9 ± 0.8  30.0 ± 0.9  0.1% (0.973) 
Diaphysis  11.0 ± 0.3  12.0 ± 0.2  8.9% (0.005) 
Dist. Metaphysis  24.1 ± 0.8  26.3 ± 1.0  9.3% (0.080) 
TIBIA (mm2)    
Prox. Metaphysis  25.2 ± 0.7  25.6 ± 0.6  1.9% (0.597) 
Diaphysis  13.7 ± 0.3  14.3 ± 0.2  4.1% (0.163) 
Dist. Metaphysis  19.2 ± 2.6  18.6 ± 0.5  -3.2% (0.821) 
VERTEBRAE (mm2)  89.5 ± 3  80.3 ± 2.1  -10.3% (0.015) 
Bone Mineral Content    
WHOLE BODY (g)  10.7 ± 0.3  9.8 ± 0.1  -8.3% (0.004) 
HUMERUS (mg)    
Prox. Metaphysis  91.9 ± 3.6  78.2 ± 3.0  -14.9% (0.006) 
Diaphysis  34.0 ± 1.1  34.3 ± 1.0  1% (0.818) 
Dist. Metaphysis  79.1 ± 3.3  74.8 ± 3.0  -5.5% (0.333) 
TIBIA (mg)    
Prox. Metaphysis  70.4 ± 2.3  64.9 ± 1.2  -7.7% (0.032) 
Diaphysis  43.4 ± 1.2  49 ± 1.1  12.9% (0.001) 
Dist. Metaphysis  64.7 ± 8.4  60.5 ± 2.5  -6.4% (0.637) 
VERTEBRAE (mg) 230.6 ± 13.1 157.3 ± 7.0  -31.8% (<0.001) 
Bone Mineral Density    
WHOLE BODY (mg/cm2)  198 ± 3  194 ± 4  -1.8% (0.472) 
HUMERUS (mg/cm2)    
Prox. Metaphysis  306 ± 7  261 ± 4  -14.9% (<0.001) 
Diaphysis  309 ± 6  286 ± 6  -7.4% (0.009) 
Dist. Metaphysis  328 ± 6  286 ± 8  -12.9% (<0.001) 
TIBIA (mg/cm2)    
Prox. Metaphysis  285 ± 5  254 ± 5  -11% (<0.001) 
Diaphysis  316 ± 5  343 ± 6  8.6% (0.002) 
Dist. Metaphysis  337 ± 5  324 ± 11  -4% (0.271) 
VERTEBRAE (mg/cm2)  255 ± 8  196 ± 6  -23.3% (<0.001) 
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Table 8. Ex-vivo DEXA results from 12-month-old rats (mean ± SD) 
 
   Control 
      n=5 
    Diabetes 
       n=5 
Difference (p-value) 
BONE AREA (cm2)    
Whole body  59.6 ± 4.68  55.8 ± 4.57  -6.5%  (0.2232) 
Whole  1.12 ± 0.09  0.88 ± 0.06  -21.1%  (0.0011) 
Humerus     Metaphysis  0.50 ± 0.04  0.39 ± 0.03  -22.9%  (0.0009) 
Diaphysis  0.21 ± 0.02  0.18 ± 0.01  -17.1%  (0.0135) 
Whole  1.42 ± 0.06  1.32 ± 0.06  -7.2%  (0.0279) 
Tibia            Metaphysis  0.70 ± 0.03  0.59 ± 0.04  -15.8%  (0.0005) 
Diaphysis  0.17 ± 0.01  0.18 ± 0.01  8.1%  (0.0019) 
Whole  0.31 ± 0.02  0.34 ± 0.04  7.9%  (0.2208) 
Metatarsal   Metaphysis  0.10 ± 0.01  0.11 ± 0.01  16.1%  (0.0491) 
Diaphysis  0.11 ± 0.01  0.11 ± 0.02  3.4%  (0.6635) 
Vertebrae  1.09 ± 0.08  0.82 ± 0.08  -24.5%  (0.0008) 
BMC (mg)    
Whole body  11.4 ± 1.0  10.1 ± 0.8  -12.0%  (0.0373) 
Whole  211.9 ± 35.8  153.3 ± 15.1  -23.7%  (0.0011) 
Humerus     Metaphysis  91.2 ± 6.0  63.2 ± 7.5  -30.7%  (0.0002) 
Diaphysis  35.8 ± 3.9  30.1 ± 2.1  -16.0%  (0.0203) 
Whole  300.7 ± 26.1  245.6 ± 22.3  -18.3%  (0.0071) 
Tibia            Metaphysis  161.7 ± 16.5  108.8 ± 9.9  -32.7%  (0.0003) 
Diaphysis  31.8 ± 1.9  36.1 ± 3.2  13.8%  (0.0309) 
Whole  25.0 ± 1.9  27.4 ± 3.2  9.4%  (0.1994) 
Metatarsal   Metaphysis  8.5 ± 0.8  8.6 ± 1.5  0.5%  (0.9573) 
Diaphysis  7.4 ± 0.6  9.0 ± 1.2  20.6%  (0.0290) 
Vertebrae  276.1 ± 37.2  169.2 ± 19.4  -38.7%  (0.0005) 
BMD (mg/cm2)    
Whole body  192.0 ±14.82  180.4 ± 4.96  -6.0%  (0.1369) 
Whole  180.4 ± 11.4  173.9 ± 6.8  -3.6%  (0.3028) 
Humerus     Metaphysis  179.6 ± 11.8  162.3 ± 8.3  -9.6%  (0.0281) 
Diaphysis  170.7 ± 12.9  172.4 ± 4.1  1.0%  (0.7777) 
Whole  211.7 ± 10.0  186.3 ± 8.7  -12.0%  (0.0027) 
Tibia            Metaphysis  229.6 ± 14.9  183.6 ± 6.5  -20.0%  (0.0002) 
Diaphysis  186.1 ± 5.8  195.9 ± 14.8  5.2%  (0.2055) 
Whole  80.5 ± 3.1  81.6 ± 1.6  1.4%  (0.4944) 
Metatarsal   Metaphysis  78.4 ± 2.3  75.9 ± 3.9  -3.2%  (0.2532) 
Diaphysis  79.2 ± 5.5  81.6 ± 1.8  3.1%  (0.3726) 
Vertebrae  252.5 ± 21.4  205.5 ± 8.9  -18.6%  (0.0019) 
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Table 9.  Ex-vivo DEXA results from 20-month-old rats (mean ± SD) 
 Control 
n=10 
Diabetes 
n=10 
Difference (p-value) 
Length (mm) 
   
TIBIA 
 47.1 ± 2.1  46.3 ± 0.8  -1.8% (0.256) 
METATARSAL 
 16.3 ± 0.4  16.2 ± 0.4  ~0% (0.673) 
Bone Area (cm2) 
   
TIBIA 
   
Whole bone 
 2.783 ± 0.227  2.772 ± 0.060  -0.4% (0.878) 
Metaphysis 
 0.837 ± 0.054  0.757 ± 0.014  -9.6% (<.001) 
Diaphysis 
 0.339 ± 0.016  0.368 ± 0.010  8.5% (<.001) 
METATARSAL 
   
Whole bone 
 0.332 ± 0.021  0.340 ± 0.022  2.4% (0.420) 
Metaphysis 
 0.116 ± 0.009  0.113 ± 0.014  -2.6% (0.577) 
Diaphysis 
 0.108 ± 0.007  0.117 ± 0.006  9.0% (0.005) 
BMC (mg) 
   
TIBIA 
   
Whole bone 
 505.8 ± 69.1  437.3 ± 21.9  -13.6% (0.008) 
Metaphysis 
 164.6 ± 26.1  112.3 ± 7.8  -31.8% (<.001) 
Diaphysis 
 57.6 ± 7.2  61.7 ± 4.6  7.2% (0.141) 
METATARSAL 
   
Whole bone 
 34.0 ± 2.9  33.5 ± 2.2  -1.3% (0.708) 
Metaphysis 
 11.3 ± 1.1  10.1 ± 1.2  -11.2% (0.024) 
Diaphysis 
 10.6 ± 1.0  11.5 ± 0.6  7.9% (0.041) 
BMD (mg/cm2) 
   
TIBIA 
   
Whole bone 
 181.2 ± 12.4  157.8 ± 6.2  -12.9% (<.001) 
Metaphysis 
 195.7 ± 20.1  148.3 ± 9.0  -24.3% (<.001) 
Diaphysis 
 169.2 ± 13.4  167.6 ± 8.9  -1.0% (0.751) 
METATARSAL 
   
Whole bone 
 102.1 ± 3.4  98.5 ± 1.5  -3.5% (0.007) 
Metaphysis 
 97.3 ± 4.8  88.8 ± 2.4  -8.8% (<.001) 
Diaphysis 
 98.5 ± 4.2  97.8 ± 2.6  ~0% (0.622) 
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ASH WEIGHT 
Table 10. Ash weight results from 12-month-old rats (mean ± SD) 
 Control 
n=5 
Diabetes 
n=5 
Difference (p-value) 
Ash Weight (mg)    
TIBIA    
Whole bone  321.1 ± 23.91  262.1 ± 18.89 
 -18.4%  (0.0025) 
Prox. Metaphysis  166.2 ± 16.54  110.5 ± 7.71 
 -33.5%  (0.0001) 
Diaphysis  50.1 ± 5.14  52.5 ± 3.41 
 4.9%  (0.4019) 
Dist. Metaphysis  36.8 ± 4.63  35.1 ± 2.6 
 -4.7%  (0.4891) 
HUMERUS 
   
Whole bone  203.6 ± 14.45  161.0 ± 14.62 
 -20.9%  (0.0017) 
Prox. Metaphysis  101.6 ± 9.74  76.9 ± 8.45 
 -24.3%  (0.0027) 
Diaphysis  45.4 ± 4.48  38.5 ± 4.06 
 -15.2%  (0.0343) 
Dist. Metaphysis  56.6 ± 2.95  45.5 ± 3.77 
 -19.5%  0.0009) 
METATARSAL  23.6 ± 1.02  24.4 ± 2.10 
 3.5%  (0.4546) 
VERTEBRAE  256.2 ± 40.19  173.9 ± 10.81 
 -32.1%  (0.0022) 
Percent Ash  (Ash wt/ dry bone wt)   
TIBIA    
Whole bone 
 62.3 ± 0.83  61.8 ± 0.51  -0.5% (0.2872) 
Prox. Metaphysis 
 60.1 ± 1.19  57.9 ± 0.85  -2.2% (0.0109) 
Diaphysis 
 67.1 ± 0.49  66.3 ± 0.23  -0.7% (0.0151) 
Dist. Metaphysis 
 58.8 ± 1.32  61.1 ± 0.84  2.3% (0.0116) 
HUMERUS 
   
Whole bone 
 62.0 ± 1.14  61.8 ± 0.87  -0.1% (0.8214) 
Prox. Metaphysis 
 59.8 ± 1.43  59.6 ± 0.9  -0.2% (0.8312) 
Diaphysis 
 66.2 ± 1.99  65.6 ± 1.11  -0.6% (0.6020) 
Dist. Metaphysis 
 62.9 ± 1.81  62.6 ± 1.88  -0.3% (0.7854) 
METATARSAL 
 59.9 ± 0.82  62.9 ± 1.11  3.0% (0.0013) 
VERTEBRAE 
 55.6 ± 2.08  56.8 ± 0.63  1.2% (0.2592) 
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Table 11. Ash weight results from 20-month-old rats (mean ± SD) 
 Control 
n=10 
Diabetes 
n=10 
Difference (p-value) 
Ash Weight (mg)    
TIBIA    
Whole bone 
 507.5 ± 68.3  438.7 ± 20.9  -13.6% (0.007) 
Metaphysis 
 158.7 ± 20.0  97.5 ± 9.5  -38.6% (<.001) 
Diaphysis 
 81.0 ± 12.4  81.5 ± 9.1  0.6% (0.926) 
METATARSAL 
 34.1 ± 3.0  32.3 ± 1.4  -5.3% (0.107) 
Percent Ash (Ashwt/ dry bone wt)   
TIBIA    
Whole bone 
 62.9 ± 1.3  61.2 ± 0.9  -2.7% (0.002) 
Metaphysis 
 56.2 ± 2.3  51.5 ± 2.0  -8.3% (<.001) 
Diaphysis 
 68.1 ± 1.1  67.1 ± 0.9  -1.4% (0.040) 
METATARSAL 
 62.7 ± 1.2  60.2 ± 1.3  -3.9% (<.001) 
 
 
Table 12. Correlation between ash weight and BMC for 
bones from 12-month-old rats expressed as 
Pearson’s correlation coefficient r (p-value). 
 Control 
n=5 
Diabetes 
n=5 
Tibia 0.974 (0.005) 0.984 (0.002) 
Humerus 0.938 (0.018) 0.912 (0.031) 
Metatarsal 0.623 (0.262) 0.933 (0.021) 
Vertebrae 0.867 (0.057) 0.989 (<.001) 
 
 
Table 13. Correlation between ash weight and BMC for 
bones from 20-month-old rats expressed as 
Pearson’s correlation coefficient r (p-value). 
 Control 
n=10 
Diabetes 
n=10 
Tibia 0.984 (<.001) 0.931 (<.001) 
Metatarsal 0.966 (<.001) 0.900 (<.001) 
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PQCT 
Table 14. Size and form of bones from 12-month-old rats (mean ± SD) 
 Control        
n=5 
Diabetes         
n=5 
Difference (p-value) 
Length (mm)    
Humerus  29.7 ± 0.76  27.4 ± 0.82  -7.7%  (0.0018) 
Tibia  40.6 ± 0.72  39.7 ± 0.95  -2.3%  (0.1150) 
Metatarsal  15.8 ± 0.17  16.2 ± 0.32  +2.9%  (0.0214) 
Vertebral body L4,L5  6.3 ± 0.28  5.8 ± 0.17  -7.9%  (0.0083) 
Cross-Sectional Area (mm2)   
Humerus Metaphysis  8.66 ± 0.932  7.80 ± 0.348  -9.9%  (0.0912) 
 Diaphysis  4.71 ± 0.273  5.31 ± 0.265  +12.7%  (0.0078) 
Tibia Metaphysis  17.91 ± 1.582  13.23 ± 0.270  -26.1%  (0.0002) 
 Diaphysis  4.90 ± 0.172  5.61 ± 0.241  +14.4%  (0.0007) 
Metatarsal Diaphysis  1.45 ± 0.091  1.68 ± 0.017  +15.3%  (0.0007) 
Vertebral Endplate  6.93 ± 0.625  6.28 ± 0.360  -9.5%  (0.0768) 
 Body             Middle  6.16 ± 0.550  6.11 ± 0.210  -0.9%  (0.8420) 
Circumferences (mm) -diaphysis   
Humerus Periosteal  7.69 ± 0.224  8.16 ± 0.203  +6.2%  (0.0078) 
 Endosteal  3.09 ± 0.167  3.55 ± 0.104  +14.7%  (0.0008) 
Tibia Periosteal  7.85 ± 0.138  8.39 ± 0.181  +6.9%  (0.0007) 
 Endosteal  3.74 ± 0.224  3.85 ± 0.134  +3.0%  (0.3714) 
Metatarsal Periosteal  4.27 ± 0.132  4.59 ± 0.023  +7.4%  (0.0007) 
 Endosteal  1.96 ± 0.134  2.29 ± 0.026  +16.9%  (0.0006) 
Cortical thickness (mm) -diaphysis   
Humerus   0.73 ± 0.026  0.73 ± 0.042  +0.4%  (0.8889) 
Tibia  0.66 ± 0.036  0.72 ± 0.027  +10.5%  (0.0092) 
Metatarsal  0.37 ± 0.004  0.37 ± 0.006  -0.6%  (0.5163) 
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Table 15. Volumetric mineral density (mg/cm3) of bones from 12-month-
old rats according to pQCT (mean ± SD) 
 Control        
n=5 
Diabetes         
n=5 
Difference 
(p-value) 
Total-metaphyseal    
Humeral metaphysis  758.4 ± 77.26  655.8 ± 17.94  -13.5% (0.0201) 
Tibial metaphysis  682.6 ± 65.83  613.5 ± 29.88  -10.1% (0.0650) 
Vertebral End plate  747.1 ± 74.92  600.0 ± 47.50  -19.7% (0.0060) 
Body               Middle  666.2 ± 73.04  517.2 ± 26.43  -22.4% (0.0027) 
Trabecular-metaphyseal    
Humeral metaphysis  339.2 ± 81.74  160.6 ± 33.36  -52.7%  (0.0019) 
Tibial metaphysis  431.9 ± 90.07  272.5 ± 32.23  -36.9%  (0.0058) 
Vertebral End plate  576.5 ± 79.01  383.2 ± 58.88  -33.5%  (0.0023) 
Body               Middle  459.8 ± 75.10  269.1 ± 18.24  -41.5%  (0.0006) 
Cortical-diaphyseal    
Humerus  1437.3 ± 5.74  1399.1 ± 16.35  -2.7%  (0.0012) 
Tibia  1331.3 ± 9.36  1314.6 ± 22.04  -1.2%  (0.1593) 
Metatarsal  1277.9 ± 12.11  1281.8 ± 7.42  +0.3%  (0.5504) 
 
 
 
Table 16. Estimated strength of diaphysis of long bones from 12-
month-old rats (mean ± SD) 
 Control 
n=5 
Diabetes 
n=5 
Difference 
(p-value) 
Cross-sectional moment of inertia (mm4)  
Humerus  3.96 ± 0.436  5.52 ± 0.672  +39.5% (0.0024) 
Tibia  3.84 ± 0.297  5.56 ± 0.565  +44.9% (0.0003) 
Metatarsal  0.29 ± 0.033  0.37 ± 0.011  +29.9% (0.0005) 
Bone  strength index (mm4.g/cm3)    
Humerus 
 5.68 ± 0.615  7.72 ± 0.989  +35.9% (0.0045) 
Tibia 
 5.11 ± 0.402  7.31 ± 0.692  +43.0% (0.0003) 
Metatarsal 
 0.37 ± 0.042  0.48 ± 0.016  +30.3% (0.0006) 
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Table 17. pQCT results from 20-month-old rats (mean ± SD) 
 Control 
n=10 
Diabetes 
n=10 
Difference 
(p-value) 
Tibial Metaphysis 
   
Cross-sectional area (mm2) 
 26.11 ± 2.95  20.81 ± 0.74  -20.3% (<.001) 
Total BMD (g/cm3) 
 0.541 ± 0.050  0.408 ± 0.029  -24.6% (<.001) 
Trabecular BMD (g/cm3) 
 0.284 ± 0.051  0.108 ± 0.038  -61.9% (<.001) 
Tibial Diaphysis 
   
Periosteal circumference (mm) 
 9.44 ± 0.46  10.22 ± 0.21  8.3% (<.001) 
Endosteal circumference (mm) 
 4.18 ± 0.26  4.93 ± 0.16  17.9% (<.001) 
Cross-sec. moment of inertia (mm4) 
 8.41 ± 1.73  12.08 ± 1.07  43.6% (0.001) 
Cortical BMD (g/cm3) 
 1.42 ± 0.01  1.42 ± 0.01  ≈0 (0.763) 
Cortical thickness (mm) 
 0.84 ± 0.06  0.84 ± 0.03  ≈0 (0.859) 
Metatarsal Diaphysis 
   
Periosteal circumference (mm) 
 4.88 ± 0.18  5.04 ± 0.07  3.4% (0.016) 
Endosteal circumference (mm) 
 2.15 ± 0.15  2.46 ± 0.09  14.3% (<.001) 
Cross-sec. moment of inertia (mm4) 
 0.51 ± 0.08  0.58 ± 0.04  13.0% (0.029) 
Cortical BMD (g/cm3) 
 1.38 ± 0.01  1.38 ± 0.02  ≈0 (0.920) 
Cortical thickness (mm) 
 0.43 ± 0.01  0.41 ± 0.01  -5.3% (<.001) 
 
 
 
IMMUNOASSAY 
Table 18. Tissue IGF-I in 12-month-old rats according to RIA (mean ± SEM) 
 Control 
n=15 
Diabetes 
n=15 
Difference (p-value) 
Tissue (µg/mg)    
Cortical bone  219 ± 55  135 ± 47  -38.3% (<0.001) 
Ankle  161 ± 42  165 ± 32  2.7% (0.766) 
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